Madeleine R. Heldman, MD, MS, discusses managing cytomegalovirus, including advances in CMV assessment and antiviral and immune strategies.

A new article outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes.

Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical ... The general term for the body’s response to ...

Triplex is designed to induce CMV-specific T cell immunity in donors ... pilot study that showed promising safety and immunological response results. The study is being conducted at three ...

The immune response goes haywire during ... to particular classes of pathogens. HSV and CMV reactivation in critically ill patients suggests a T cell defect, and studies in ICU patients ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Previous work by the team had shown that the NOTCH signaling pathway played a central role in differentiation, which is essential for an effective immune response by CD8 + T cells. In the new ...

EVAX READ THE FULL EVAX RESEARCH REPORT Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting ...